FDA Rejection Triggers Major Stock Collapse and Legal Action
Corcept Therapeutics Incorporated ($CORT) is facing significant legal and financial headwinds following the FDA's rejection of its New Drug Application (NDA) for relacorilant on December 31, 2025. The regulatory setback prompted an immediate and severe market response, with the company's stock price plummeting 50.42% in the aftermath of the announcement. The dramatic decline has now triggered a class action securities fraud lawsuit filed by Glancy Prongay Wolke & Rotter LLP, one of the nation's most active securities litigation firms, which is actively seeking shareholders who suffered losses to join the litigation.
The lawsuit alleges that Corcept failed to adequately disclose material information to investors regarding the regulatory challenges facing its flagship drug candidate. According to the complaint, the company did not properly inform shareholders that the FDA had previously communicated serious concerns about the clinical development program and had warned that it expected to raise significant review issues during the NDA evaluation process. This alleged failure to disclose known regulatory risks represents a classic securities fraud claim—one that focuses on the company's duty to provide material, truthful information to investors.
The Relacorilant Program and Regulatory History
Relacorilant was poised as a potentially significant therapeutic asset for Corcept Therapeutics, a biopharmaceutical company focused on the development of cortisol modulators and other novel therapies. The drug candidate had been under development for what the company presumably believed would be a viable path to FDA approval. However, the regulatory journey proved far more complicated than investors may have been led to believe.
The FDA's rejection—coming on the final day of 2025—suggests that the agency's concerns materialized into a formal denial. Key allegations in the securities lawsuit include:
- Prior FDA warnings about deficiencies in the clinical development program
- Expectations of significant review issues that should have been disclosed to the market
- Failure to warn investors of the magnitude of regulatory risk
- Material omissions regarding known FDA objections and anticipated challenges
The timing of the disclosure and the severity of the stock price decline suggest that investors did not have adequate visibility into these regulatory headwinds before the formal rejection.
Market Context: Biotech Volatility and Regulatory Risk
The collapse of $CORT reflects a broader challenge facing the biotechnology sector: regulatory risk is often the single largest driver of volatility for drug development companies. Unlike large-cap pharmaceutical firms with diversified product portfolios, smaller biotech companies like Corcept can be dramatically affected by the success or failure of a single asset.
The FDA's NDA review process is designed to be rigorous, but public companies have a legal obligation to disclose material information as it becomes known. When the FDA signals serious concerns during the development phase, particularly if those concerns suggest likely rejection, investors argue they deserve to know about it. The gap between what management knew about regulatory challenges and what was communicated to shareholders is precisely what securities fraud litigation targets.
This case also highlights the importance of transparent FDA communication in biotech investing. Companies that actively communicate with regulators and update investors on feedback loops tend to experience less dramatic stock swings when rejections occur. By contrast, companies that appear to withhold negative regulatory signals face not only the operational challenge of a failed program but also reputational damage and legal exposure.
Investor Implications and Shareholder Consequences
For Corcept Therapeutics shareholders, the implications are multifaceted:
Immediate Financial Impact: The 50.42% stock decline represents a massive destruction of shareholder value. Investors who held the stock through the FDA rejection face significant losses. For those who can demonstrate they held shares during the alleged period of misleading statements or omissions, the securities lawsuit provides a potential avenue for recovery, though litigation outcomes are uncertain and can take years to resolve.
Capital Structure Risk: The loss of the relacorilant program eliminates a major revenue pipeline for the company. Corcept will need to reassess its strategic direction, which may require additional capital raises through equity offerings or debt issuance—both of which could further dilute existing shareholders.
Pipeline Dependency: The company's future prospects now depend on its remaining pipeline assets. Investors will closely scrutinize what other programs Corcept has in development and whether they have sufficient capital to advance those programs without further dilution.
Litigation Risk Premium: Companies facing active securities litigation often trade at discounts as investors price in legal settlement costs, management distraction, and reputational damage. $CORT may trade at a depressed valuation for some time as the litigation proceeds.
The lawsuit also raises questions about management accountability and corporate governance. Shareholders will want clarity on whether board-level discussions about FDA feedback were adequately documented and whether disclosure committees properly evaluated the materiality of regulatory feedback.
Forward-Looking Considerations
As the class action litigation proceeds, key questions will emerge about Corcept's knowledge of FDA concerns at various points in time, the company's disclosure practices, and what information was communicated to investors versus what was known internally. Glancy Prongay Wolke & Rotter LLP has built its reputation on prosecuting complex securities cases, and the presence of a clear stock price catalyst—the December 31, 2025 FDA rejection—provides a strong factual foundation for the litigation.
For investors considering $CORT at current depressed levels, the key decision point involves whether the company has sufficient remaining assets and capital to survive and potentially thrive, or whether the loss of relacorilant is a terminal event for the enterprise. Additionally, investors should monitor the litigation timeline, as settlements or judgments could materially impact the company's financial position.
This case serves as a reminder of the importance of regulatory transparency in biotech investing and the consequences companies face when material information is withheld from the market. Whether Corcept can recover from this combination of operational failure and legal exposure will become apparent in the coming months as the litigation develops and the company outlines its strategic plan.